A superior heterologous prime‐boost vaccination strategy against COVID‐19: A bivalent vaccine based on yeast‐derived RBD proteins followed by a heterologous vaccine

Documenti analoghi

• Blended BA.5 infection within 8 days after a boosted bivalent mRNA vaccination strengthens and lengthens the host immunity
  di: Mingzhu Huang, et al.
  Pubblicazione: (2024)
• Neutralizing antibody response after immunization with a COVID‐19 bivalent vaccine: Insights to the future
  di: Milena Silva Souza, et al.
  Pubblicazione: (2024)
• Neutralizing antibody response to SARS‐CoV‐2 bivalent mRNA vaccine in SIV‐infected rhesus macaques: Enhanced immunity to XBB subvariants by two‐dose vaccination
  di: Julia N. Faraone, et al.
  Pubblicazione: (2024)
• Evolving dynamics of COVID‐19 vaccine hesitancy in China: Perspectives and suggestions from Taiwan
  di: Feng‐Li Lin, et al.
  Pubblicazione: (2024)
• JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV
  di: Giulia Matusali, et al.
  Pubblicazione: (2024)